Tech Company Financing Transactions
ORIG3N Funding Round
ORIG3N closed a $20 million funding round on 6/28/2017. Investors included Hatteras Venture Partners, DEFTA Partners and private investors.
Transaction Overview
Company Name
Announced On
6/28/2017
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Undisclosed
Investors
Hatteras Venture Partners (Lead Investor) (Clay Thorp)
private investors (Byron Smith)
Proceeds Purpose
The continued support of our existing investors and the confidence of our new investors will enable us to expand and intensify our research efforts into the development of cell therapies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
27 Drydock Ave. 3rd Floor
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Website
Email Address
Overview
Boston based ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver and neurodegenerative indications. These treatments are based upon Nobel Prize winning technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robin Smith
Chief Medical Officer
Michael Fang
Chief Operating Officer
Kate Blanchard
VP - Marketing
Jish Mukerji
Browse more venture capital transactions:
Prev: 6/28/2017: Souktel venture capital transaction
Next: 6/28/2017: Polybit venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs